Drug Trial Radar · NCT01377220
Evaluation of 11 C-Choline PET-CT for Detection of Hepatocellular Carcinoma
Last checked: Nov 20, 2026Latest source record: Jun 21, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
30
Planned (sponsor's estimate)
Start
Jun 2011
Primary completion
Jun 2013
Study completion Jun 2014
Sponsor
- Lead sponsor
- Commissariat A L'energie AtomiqueGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- Collaborators
- Assistance Publique - Hôpitaux de Paris
- First posted
- Jun 21, 2011
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Hepatocellular carcinoma (HCC)is the most frequent primitive tumour of the liver. Recently, several research studies reported that 11C-choline PET has shown a high detection rate of well differentiated HCC, which is an early stage of primary liver cancer. The aim of this study was to prospectively evaluate the diagnostic accuracy of 11C-choline PET-CT to detect HCC in cirrhotic or non cirrhotic patients.
Conditions
- Hepatocellular Carcinoma
Interventions
11C-CholineDrug
11C-Choline : 6MBq/kg on direct intravenous on one minute.
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CEA-SHFJ
Orsay, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.